Donatello Crocetta, Chief Medical Officer at UCB, said: “These results for bimekizumab show meaningful improvements in inflammatory lesions and skin pain to three years, and offer a valuable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback